Neuroantibodies: Ectopic expression of a recombinant anti-substance P antibody in the central nervous system of transgenic mice  by Piccioli, Patrizia et al.
Neuron, Vol. 15, 373-384, August, 1995, Copyright © 1995 by Cell Press 
Neuroantibodies: Ectopic Expression 
of a Recombinant Anti-Substance P Antibody 
in the Central Nervous System of Transgenic Mice 
Patrizia Piccioli,*t Anna Di Luzio,t Rainer Amann,§ 
Rufina Schuligoi,§ M. Azim Surani,$ Josef Donnerer,§ 
and Antonino Cattaneo*t 
*International School for Advanced Studies (SISSA) 
International Center for Genetic Engineering 
and Biotechnology 
Via Beirut 2-4 
34013 Trieste 
Italy 
tCNR Institute of Neurobiology 
Viale Karl Marx 43 
00137 Rome 
Italy 
tThe Wellcome/CRC Institute 
Tennis Court Road 
Cambridge CB2 1QR 
England 
§lnstitut fuer Experimentelle und Klinische Pharmakologie 





Recombinant antibodies are efficiently secreted by 
cells of the nervous system. Thus, their local expres- 
sion in the CNS of transgenic mice could be used to 
perturb the function of the corresponding antigen. As 
a first application of this approach, we have generated 
transgenic mice that express antibodies against the 
neuropeptide substance P, under the transcriptional 
control of the promoter of the neuronal gene vgf. The 
transgenic antibodies are expressed in a tissue- 
specific and developmentally regulated manner and 
are effective in competing with the endogenous sub- 
stance P, as demonstrated by a marked inhibition of 
neurogenic inflammation and by motor deficits. This 
phenotypic knockout approach may provide a comple- 
mentary alternative to gene knockout by homologous 
recombination. 
Introduction 
Substance P (SP), a neuropeptide of the tachykinin family, 
exerts several biological activities in the CNS and in pe- 
ripheral organs, mainly, but not exclusively, as a neuro- 
transmitter and neuromodulator ( eviewed in Otsuka and 
Yoshioka, 1993). The functional roles of the SP neuropep- 
tide in the mammalian CNS and PNS are currently being 
investigated by a variety of experimental approaches, in- 
cluding the use of antibodies and of pharmacological go- 
nists and antagonists. However, a continuous delivery of 
antibodies or pharmacological drugs to the nervous tissue 
poses several practical problems, mainly due to limited 
diffusion and half-life of the injected substance. Moreover, 
the long-term use of pharmacological gonists and antag- 
onists in vivo is also limited by secondary nonspecific ef- 
fects. 
Following the demonstration that cells of the nervous 
system are very efficient in the secretion of recombinant 
antibodies (Cattaneo and Neuberger, 1987), we have de- 
veloped an experimental approach (neuroantibodies) for 
functional and developmental studies in the nervous sys- 
tem, based on the ectopic expression of recombinant anti- 
bodies by cells of the nervous system itself (Piccioli et 
al., 1991), achieved by a suitable choice of transcriptional 
regulation sequences to direct the expression of an anti- 
body of interest. 
This strategy was applied to the study of the neuropep- 
tide SP, as this neuropeptide has multiple sites of action 
in both the PNS and CNS. We took advantage of the rat 
monoclonal antibody NC1/34HL (Cuello et al., 1979), 
which recognizes with a high affinity the amidated C-terminal 
portion of the SP peptide responsible for receptor binding, 
and does not cross-react with the related tachykinin pep- 
tides neurokinin A (NKA) and neurokinin B (NKB). In this 
paper we present the results concerning the generation 
and the study of transgenic mice that express recombinant 
anti-SP antibodies (Piccioli et al., 1991) under the control 
of the promoter of the neuronal vgfgene (Levi et al., 1985), 
which encodes for a protein that is induced in vitro by 
nerve growth factor (NGF) in PC12 cells (Levi et al., 1985) 
and is stored in secretory granules of cells of neuronal 
and endocrine origin (Possenti et al., 1989). VGF RNA and 
protein are expressed in vivo in discrete cell populations of 
the CNS and PNS, as well as in the adrenal medulla (van 
den Pol et al., 1989, 1994; Ferri et al., 1992; Salton et 
al., 1991). Many of these regions show SP and/or NK1 
receptor expression as well. We show here that the recom- 
binant antibodies are expressed in both the PNS and CNS, 
with a postnatal spatiotemporal pattern of expression that 
parallels that of the endogenous vgf gene. The phenotypic 
effects caused in adult mice by the expression of 
transgenic antibodies were assessed by functional assays 
related to the SP peptidergic system, including acute noci- 
ception, neurogenic inflammation, and motor and explor- 
atory behavior, and confirm that the neutralization of SP 
action is effective in this mouse model. This report proves 
that the neuroantibody approach (Cattaneo and Neuberger, 
1987; Cattaneo et al., 1989, Soc. Neurosci., abstract; Pic- 
cioli et al., 1991) can be utilized to interfere in vivo with the 
action of a target neuronal antigen. The results obtained 
provide a valuable model for the study of SP actions and 
of vgf transcriptional regulation. Moreover, these results 
suggest that the neuroantibody approach may be useful 
for studying ene function in the CNS, as a complementary 
alternative to gene knockout by homologous recombina- 
tion. In particular, this approach should prove valuable for 
those genes, such as that coding for preprotachykinin, 
whose expression is regulated in a subtle way by alternate 




Production and mRNA Analysis of Transgenic Mice 
Expressing Anti-SP Antibodies under the 
Transcriptional Control of the vgf Promoter 
The rat monoclonal antibody NC1/34HL (Cuello et al., 
1979) is directed against the amidated C-terminal portion 
of the SP neuropeptide, which is responsible for receptor 
binding (Otsuka and Yoshioka, 1993). This antibody is 
therefore effective in inhibiting the binding of SP to its 
receptors and the ensuing biological actions (Bannon et 
al., 1983). Moreover, NC 1/34H L does not cross-react with 
the related neurokinin peptides NKA and NKB, which dif- 
fer from SP by only one residue in the C-terminal penta- 
peptide. With the aim of neutralizing SP action in vivo by 
the neuroantibody strategy, the variable regions of the 
antibody have been previously cloned and reassembled 
with human constant regions instead of the original ones, 
to facilitate the subsequent detection of the transgenic 
antibody chains against the background of mouse immu- 
noglobulins (Piccioli et al., 1991). For the present study, 
we selected the promoter of the rat vgf gene (Levi et al., 
1985) to direct antibody expression in the nervous system 
of transgenic mice. A 1.5 kb DNA region 5' to the initial 
methionine (hereafter referred to as the "vgf promoter") 
directs a strong expression f a reporter gene in neuronal 
cultured cells (Possenti et al., 1992). The heavy and light 
chains of the recombinant NC1 anti-SP antibody were 
placed under the transcriptional control of the vgf promoter 
region in separate plasmids (Figures 1A and 1B), and the 
transcriptional efficiency of these plasmids was confirmed 
by transfection in nonlymphoid cells permissive for this 
promoter, such as PC12 (pheochromocytoma) cells and 
GH3 (pituitary) cells. 
For the production of vgf anti-SP transgenic mice, the 
linearized DNA from both plasmids (Figures 1A and 1B) 
was coinjected into the pronucleus of fertilized mouse 
eggs; 33 mice were born after egg implantation. Of these, 
4 had DNA for both chains integrated, and 1 had the light 
chain transgene only (founder 8507). Of the double 
transgenics, 2 did not transmit he transgenes to offspring, 
and 1 (founder 8530) expressed the transgenes at lower 
levels. Therefore, we concentrated ourstudies on the dou- 
ble-positive (8510) and single-positive (8507) founders, but 
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Figure 1. Production and mRNA Analysis of Transgenic Mice Ex- 
pressing Anti-SP Antibodies 
(A and B) DNA constructs used for the production of the transgenic 
mice. Light chain (A) and heavy chain (B) transgenes were used to 
generate transgenic mice by microinjection in fertilized 1-cell eggs. 
Linearized DNA was prepared by digestion with Pvul (light chain) and 
HindllI-Bglll (heavy chain) of pSVhygro-VGF-VKSP and pSVgpt-VGF- 
V.SP, respectively (Piccioli et al., 1991). CK and CH1-CH3, human 
constant region domains of the light (K) and heavy (71) chains; EH 
and EK, enhancers of the immunoglobuiin heavy and light chain genes, 
respectively; V~ and V., light and heavy chain variable regions of the 
NC1/34HL monoclonal antibody; XTp, 5' region of the vgf gene (from 
-806 to +693 of the transcription initiation start), encompassing the 
putative promoter region and a spliced intron just upstream of the 
initiating methionine codon (Possenti et al., 1992); the closed boxes 
in the light chain construct refer to vector sequences. Scale, 1 cm = 
1000 bp (A) or 400 bp (B). 
(C) Southern blot analysis of F1 and F2 progeny of transgenic mice 
derived from founder 8510 (lanes 1-7) and founder 8530 (lanes 8- 
12). DNA (20 I~g) was digested with BamHI and hybridized using the 
3 kb BamHI-Bglll fragment (C7 probe; see [B]) as a probe. Results 
for the heavy chain transgene are shown. A 5.6 kb band lights up, 
corresponding to head-to-tail insertions of multiple copies of transgenes. 
(D) RNase protection analysis of the transgenic antibody chains. Re- 
sults for the light chain are shown. Total RNA was extracted from 
brains of adult wild-type (lanes 4 and 8) and vgf transgenic (lanes 
1-3 and 5-7) mice. Total RNA (20 p,g) was hybridized to a ~P-labeled 
antisense RNA probe specific for the 3' terminal end of the rat vgf 
gene in the absence (lanes 1-4) or presence (lanes 5-8) of a V,-specific 
antisense RNA probe. A 510 bp protected fragment, specific for the 
endogenous vgf gene, is observed in transgenic (lanes 1-3 and 5-7) 
and wild-type (lanes 4 and 8) mice, as expected, while a protected 
band corresponding to the transcript from the V. transgene is evident in 
the brain of transgenic mice (lanes 5-7). Numbers on the left represent 
molecular size (in kilobases) as derived from a 3ZP-labeled pBR322- 
Mspl marker (lane 9); vgf and V, RNA probes digested in the absence 
of added RNA are also shown (lane 10). 
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results on the expression pattern of the transgene were 
also confirmed on mice from family 8530. Homozygous 
transgenic mice obtained after breeding are viable, but 
they mate and reproduce at a greatly reduced rate. Al- 
though this effect has not been systematically quantitated, 
it limited significantly the number of mice available for 
experimental study with respect to their single transgenic 
or nontransgenic ounterparts. This phenotypic effect is 
consistent with reports that neonatal capsaicin treatment 
leads to a marked reduction of the mating and reproduc- 
tion rate of both male and female rats, presumably a sen- 
sory fiber-mediated phenomenon (Traurig et al., 1984). 
In a separate set of microinjections, transgenic mice were 
derived with the same transgenic antibody under the tran- 
scriptional control of the immunoglobulin heavy chain pro- 
moter (P. P. and A. C., unpublished data). One of the 
families derived (family 8) was utilized for some of the 
experiments described below. 
Figure 1C shows a Southern blot for the heavy chains on 
DNA samples from individual mice deriving from founders 
8510 and 8530 (both double-positive transgenics), which 
confirms that an identical restriction pattern is obtained 
for the mice within each group and shows that more than 
one copy of each transgene is integrated, in a head-to-tail 
arrangement. 
The expression of the transgenes in different organs of 
adult mice was first verified at the mRNA level, by RNase 
protection analysis. Figure 1D shows that the mRNA for 
the NC1/34HL light chain is expressed in the brain of adult 
transgenic mice (Figure 1D, lower arrow). The levels of 
mRNA for the transgenic antibody chain appear to be 
lower than those of the abundant endogenous vgf mRNA 
(Figure 1D, upper arrow), suggesting that sequences in 
the 3' or 5' untranslated regions of the vgfgene, not present 
in our construct, may contribute to increased mRNA lev- 
els, possibly by increasing its transcription or its stability. 
RNase protection analysis of different issues showed that 
V~ and vgf mRNAs were detected in brain, but not in kid- 
ney, liver, spleen, and total adrenal glands (data not 
shown), mRNA for the transgenic light chain was detect- 
able in cerebellum and spinal cord at low levels, while vgf 
transcripts could be more easily detected there (data not 
shown). Qualitatively similar results were obtained for the 
heavy chain mRNA, although the levels of mRNA appear 
to be lower. This is most likely due to secondary structure 
of the V. mRNA and does not reflect a genuine difference 
in the levels of mRNA for the light and heavy chains, as 
this difference is also found with the mRNA isolated from 
the NC1 hybridoma cell line (data not shown) and as the 
heavy chain protein can be very easily detected (see 
below). 
The postnatal expression of antibody chain mRNA in the 
brain, which was confirmed in litters from 2 independent 
founders (8510 and 8530), peaks around P10-P12 and 
declines thereafter (data not shown), in very close 
agreement with the expression of vgf mRNA (Salton et 
al., 1991). 
In conclusion, the expression of the transgene mRNA(s), 
transcribed from the vgf promoter, appears to parallel that 
of the endogenous vgf gene. 
Functional Anti-SP Antibodies Are Synthesized in 
the Brain and in the Serum of Transgenic Mice 
We then asked whether the chimeric anti-SP antibodies 
are functional. As the binding of NC1/34HL to SP requires 
both the heavy and light chains and the isolated NC1/34HL 
chains alone do not retain SP-binding activity (Piccioli et 
al., 1991), functional antibodies can be made only if the 
two antibody chains are coexpressed in the same cells. 
Heavy and light chain assembly cannot occur extracellu- 
lady to any significant extent, and moreover, the heavy 
chain alone cannot be secreted in the absence of a light 
chain. 
The presence of transgenic SP-binding antibodies in the 
serum was determined at different postnatal ages, with 
an enzyme-linked immunosorbent assay (ELISA) on solid 
phase-coupled SP peptide (Figure 2A). Two main conclu- 
sions can be drawn from this experiment. First, SP-binding 
antibodies can indeed be detected in the serum, demon- 
strating assembly (and therefore coexpression) of the two 
antibody chains. These antibodies are most likely pro- 
duced in endocrine tissues, such as the adrenal medulla 
and the pituitary, where the vgf gene is expressed (Ferri 
et al., 1992). Second, the level of SP-binding transgenic 
antibodies in the serum appears to be developmentally 
regulated, increasing after birth up to a maximum value 
around the second to third postnatal week, after which it 
falls down. This is consistent with the developmental time 
course seen at the mRNA level (see above) and was fu rther 
confirmed by the immunocytochemical analysis described 
below. The serum of adult mice (2-10 months old, families 
8510 and 8) was shown not to contain mouse immunoglob- 
ulins directed against human transgenic antibodies (data 
not shown). 
The amount of recombinant antibody found in the serum 
was also quantitated by incubation with 1251-labeled SP 
peptide (Figure 2B). This yields an average value of 60 
ng/ml for the concentration of chimeric SP antibodies in 
the serum of 3-week-old transgenic mice, as determined 
by comparison to a calibration curve with purified NCI/ 
34HL antibody. In the adult, these levels fall to 6 ng/ml. 
The levels determined in the serum for the vgf anti-SP 
mice are comparable to those found in the serum of family 
8 mice (~2.5 ng/ml). Negative controls in these assays 
included serum samples from the family 8507 transgenic 
mice, which express only the light chain. The binding of 
1251-SP to transgenic antibodies is competed by a molar 
excess of unlabeled SP (data not shown), further confirm- 
ing the specificity of the binding. 
This assay was used to demonstrate the presence of 
SP-binding antibodies in different brain regions at the ages 
of P21 (Figure 2B) and 3 months (Figure 2C), thus confirm- 
ing that coexpression of heavy and light chains, to yield 
a functional antibody, is indeed occurring in cells of the 
nervous system. At 3 weeks, the highest levels of antibod- 
ies are found in the cortex and hippocampus, followed by 
pons, hypothalamus, and cerebellum (Figure 2B). Interest- 
ingly, antibodies are also present in the adrenal gland, in 
keeping with the expression of vgf in the adrenal medulla 
(Ferri et al., 1992). It should be noted that this assay, based 
on the binding of exogenously added ~2sl-SP, could under- 
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estimate the amount of antibody present, owing to the 
presence of endogenous SP that competes with theanti- 
bodies, following tissue extraction. In the adult vgf mice, 
transgenic antibodies can be readily detected in different 
brain regions, albeit at lower levels (Figure 2C). In 3-month- 
old family 8 mice (immunoglobulin promoter), anti-SP anti- 
bodies can be detected in the serum (-2.5 ng/ml) and in 
the spinal cord (40 ng/mg $100). 
Distribution of Tranagenic Anti-SP Antibodies 
in the CNS 
The spatial distribution of anti-SP antibodies in the CNS 
was studied by im munocytochemistry. The general cytoar- 
chitectonic structure of brain regions did not reveal any 
obvious alteration in the transgenic mice. The overall pic- 
ture is that of an abundant staining of many discrete areas 
throughout he nervous system, with a predominantly, if 
not exclusive, neuronal expression. Figure 3 and Figure 
4 illustrate some examples of the staining obtained for 
the heavy chain in coronal brain sections derived from 
transgenic mice at P16. An abundant antibody expression 
can be seen in the piriform and perirhinal cortex, as well 
as through the amygdaloid complex (Figure 3A). Figure 
3B shows the distribution of the transgenic heavy chain 
in the hippocampal region. A stronger d nsity of positive 
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Figure 2. Postnatal Expression of the Recombinant Anti-SP Antibody 
in the Serum and in Tissues of Transgenic Mice 
(A) ELISA on blood samples at different postnatal ages. Blood was 
collected from transgenic and negative mice, and serum was tested 
by ELISA for the presence of human antibodies binding to solid-phase 
SP. Data are reported as fold of induction over the background value 
(obtained for samples from negative age-matched controls, value 
equal to 1), calculated as the ratio between the absorbance values 
for positive and negative mice in each assay. Values reported repre- 
sent the average of data collected in four separate experiments for 
adult animals (np = 23, nc = 9); in two experiments for P2 (np = 6, 
nc = 2), P8-P10 (np = 10, nc = 7), and P16-P18 (rip = 15, nc = 
4) mice; and in one single experiment for P23-P40 (np= 8, nc = 4) 
and P50-P75 (np = 11, nc = 9) mice (np, number of double-positive 
mice tested; nc, number of single-positive and/or negative mice 
tested). Bars indicate _+ SEM. 
(B and C) SP-binding antibodies in CNS regions of P20 (B) and adult 
(C) transgenic mice. Brain regions, spinal cord, and adrenal glands 
were dissected from P20 and adult (3-month-old) transgenic mice, and 
the presence of ~2sI-SP-binding transgenic antibodies was determined 
(see Experimental Procedures). Data are reported as nanograms of
antibody present in 100 mg of pooled $100 extracts (see Experimental 
Procedures) and represent the results obtained for transgenic mice 
(n = 6) after subtracting the background values obtained for control 
mice (n = 5). Each pooled extract was assayed in three to four different 
experiments, and the differences between each experimental determi- 
nation were always less than 10%. The amount of antibody present 
was determined by comparison to titration curves, performed in each 
experiment, with purified NC1 antibodies. Hi, hippocampus; Cx, cor- 
tex; Br*, the rest of the brain, after dissection of the indicated regions; 
Hy/Th, hypothalamus/thalamus; Cb, cerebellum; P, pons; S, spinal 
cord; Adr, adrenal gland; BI#, determination of anti-SP antibodies in 
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Figure 3. Ectopic Expression of Recombinant 
Anti-SP Antibody Chains in the CNS of Trans- 
genic Mice 
Results for the heavy chain are shown; 50 p.m 
coronal sections of the brain from a double- 
transgenic mouse sacrificed at P16. Expres- 
sion of the heavy chain can be seen in the piri- 
form and perirhinal cortex as well as throughout 
the amygdaloid complex (A), and in the hippo- 
campus (B). A neuron-specific staining can be 
observed in (C), which shows, at higher magni- 
fication, a pyramidal cell of the hippocampal 
CA1 region (arrow in [B]). Bars, 240 izm (A and 
B), 24 p.m (C). 
cells can be found throughout the hippocampal formation. 
A pyramidal cell of CA1 reacting positively for the heavy 
chain is shown in Figure 3C. The high levels of transgenic 
antibodies found in the hippocampus are particularly note- 
worthy in view of the fact that SP and SPergic nerve termi- 
nals are also abundantly present in the hippocampus, sub- 
serving a functional role that is still unclear (Leranth and 
Nitsch, 1994). Among other brain regions, all cortical areas 
(Figures 4A and 4B) as well as olfactory nuclei and tuber- 
cles also show good expression of the transgenic antibod- 
ies, while thalamic nuclei show a lower density of strongly 
reactive cells (e.g., Figure 4D). Spinal cord, where SP 
plays important roles, also shows positively staining neu- 
rons (Figures 4E and 4F). A high density of strongly re- 
acting neurons is also found in other brain regions, such 
as the central gray and reticular formations, while striatum, 
caudate putamen, and hypothalamus show scattered pos- 
itively staining neurons. Of other CNS regions where SP 
is present at high levels, substantia nigra proved to be 
consistently devoid of antibody expression. It remains to 
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Figure 4. Types of Neuronal Cells Expressing Antibody Heavy Chains in the Nervous System of Transgenic Mice 
(A) Bipolar cells of the piriform cortex; (B) pyramidal neurons of the frontal cortex (magnification of [S]); (C) pyramidal cells from the CA2-CA3 
hippocampal fields (sagittal section); (D) multipolar thalamic neuron; (E and F) scattered neurons surrounding the ependymal canal in thoracic 
sPinal cord. A punctate staining is evident in this case, probably reflecting secretory vescicles. Bars, 24 p.m (A, D, E, and F), 48 p.m (B and C). 
be verified by radioimmunoassay whether antibodies re- 
leased by nearby regions are present in the striatonigral 
system. 
Inspection at a higher magnification shows that the 
staining is mainly, if not exclusively, neuronal, with neu- 
rons of many different morphologies being found in differ- 
ent brain regions (Figure 4; neurons from piriform cortex 
[A], frontal cortex [B], CA2 field of the hippocampus [C], 
thalamus [D], and spinal cord [E and F]). These pictures 
show that the staining is distributed throughout the cell 
extension, including its cellular processes and arboriza- 
tion. It will be extremely interesting to analyze with electron 
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microscopic imm unochemistry the fine intracellular distri- 
bution of the transgenic antibodies, with particular egard 
to the synaptic regions. 
A comparison of the immunocytochemical staining ob- 
served in sections of P16 transgenic mice with that ob- 
tained for adult mice confirmed that the expression of the 
transgenic antibody is higher in the former case and de- 
clines in the adult (in terms of number of labeled cells), 
as already described above for the titer of the transgenic 
antibodies in serum. A very similar, almost superimpos- 
able pattern of expression is found for the light chain, both 
in the single- and double-transgenic mice. This rules out 
chromosomal integration effects on the expression pattern 
of the transgenes. 
Although a systematic comparison of the antibody ex- 
pression with VGF expression in the mouse brain (van den 
Pol et al., 1994) was not performed, the overall expression 
patterns of the two genes are remarkably similar, which 
supports the conclusion that the 1.5 kb promoter region 
of the vgf gene contains most (if not all) of the elements 
necessary to determine its tissue specificity. Thus, the 
transgenic antibody chains can be considered as reporter 
genes for the activity of vgf regulatory sequences. This 
mouse model can therefore be used to address the ques- 
tion of the sensitivity of vgf gene regulatory sequences to 
induction by NGF, by other neurotrophins, and by electri- 
cal activity in vivo (Lombardo et al., 1994). 
Quantitative and qualitative differences between the ex- 
pression patterns of the transgenic antibodies and the en- 
dogenous vgfgene, however, can be seen. These could be 
ascribed to the lack of some other unidentified regulatory 
element(s) in the transgene construct utilized; to the fact 
that the expression of endogenous vgf has been studied, 
in the published reports, after colchicine treatment, to facil- 
itate the detection of VGF immunoreactivity in cell bodies 
(van den Pol et al., 1989, 1994); to effects of the anti-SP 
antibodies on the expression of the vgf gene itself; or to 
differences between vgf expression in the mouse and in 
the rat. This will require further investigation. 
Functional Studies Related to the SP System 
We performed functional experiments to ask whether anti- 
body expression is efficient in competing some of the ac- 
tion(s) of endogenous SP. 
In the periphery, there is good evidence that SP is in- 
volved in the process of neurogenic inflammation (Lem- 
beck and Holzer, 1979; Lembeck et al., 1992). Its role in 
nociception has been controversial (Urban et al., 1994), 
possibly being only one of several transmitters. In the 
CNS, SP has been implicated in a variety of functions 
(Otsuka and Yoshioka, 1993), including control of motor 
activities through a net excitatory input of SP in the stria- 
tonigral system and a potential neuroendocrine role of hy- 
pothalamic SP. In these mice, we have tested acute noci- 
ceptive behavior (tail immersion and hot plate test), 
neurogenic inflammation upon mustard oil application on 
the skin, and motor activity and exploratory behavior in 
the open field test. For practical reasons, these functional 
tests were performed on adult (3-month-old) mice, even if 
the levels of the antibody are lower in adult than in younger 
animals (Figures 2B and 2C). 
The reaction times in the hot plate test and the tail with- 
drawal latencies did not differ in anti-SP transgenic mice 
with respect to age-matched controls (Figure 5A). On the 
contrary, mustard oil-induced plasma protein extravasa- 
tion was significantly reduced in mice expressing the anti- 
SP antibody (65% reduction; Figure 5B, part I). Tests for 
motor activity were also performed, as a simple inspection 
of the transgenic mice showed that they were quiter and 
less scared upon handling, allowing blind observers to 
distinguish them from their normal or single-transgenic 
littermates. Consistent with this observation, a decreased 
locomotor activity was demonstrated for the transgenic 
mice in the open field test, with a very significant reduction 
of line crossings and rearings (Figure 5C, part I). 
The inhibition of neurogenic inflammation by anti-SP 
transgenic antibodies was confirmed on another indepen- 
dent line of transgenic mice (family 8; Figure 5B, part II). 
The expression of the anti-SP antibodies in these mice is 
directed by the immunoglobulin promoter, and the re- 
sulting levels in the serum are comparable to those of 
age-matched mice from family 8510, as determined by 
binding of 12sI-SP. Also in mice from family 8, the plasma 
extravasation following neurogenic inflammation was in- 
hibited close to 40%. On the other hand, family 8 mice 
did not show the decrease in motor activity observed for 
the vgf anti-SP mice (Figure 5C, part II), consistent with 
the expected reduced expression of the transgenic anti- 
bodies in the CNS of these mice. Preliminary observations 
did not point toward any effect on acute nociceptive behav- 
ior in these mice. 
Altogether, these results show that the neutralization of 
the SP peptide by the expression of recombinant antibod- 
ies is functionally effective. 
It was of interest to determine whether the expression 
of the transgenic antibodies affects the levels of the endog- 
enous SP peptide. Indeed, it is expected that inhibition of 
SP activity in vivo should occur by a competitive ffect at 
the level of peptide binding to the receptors, and not by 
an effect on the level of the peptide itself. SP levels were 
determined by radioimmunoassay in brain samples from 
negative and transgenic mice (Table 1). For midbrain and 
medulla, it was confirmed, as initially anticipated, that SP 
levels in transgenic mice were identical to those in con- 
trols. Surprisingly, in spinal cord and sciatic nerve, a small 
but significant increase of SP levels was observed in 
transgenic mice. We do not know at this stage whether this 
feedback mechanism is activated at the transcriptional, 
translational, or posttranslational level, or whether it in- 
volves other neuropeptides and/or transmitters as well. 
The expression of the preprotachykinin mRNA in the stria- 
tum of vgfanti-SP mice was shown not to differ from those 
of control mice (data not shown). Also, imm unohistochem- 
istry of the SP peptide itself throughout he CNS did not 
show any gross difference with the controls (data not 
shown). Future studies will be needed to clarify further this 
putative feedback mechanism uncovered by the action of 
the transgenic antibodies. 
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Figure 5. Functional Tests of SP Action 
Thermonociception (A) was evaluated by the 
reaction time in the hot plate test and by the tail 
withdrawal latency from 50°C water (stippled 
bars, control [n = 8]; closed bars, family 8510 
[n = 7]). Neurogenic plasma protein extravasa- 
tion (B) was evoked in the hind paw by challeng- 
ing with 5% mustard oil in paraffin oil (part I, 
family 8510; part II, family 8; see Results). Mo- 
tor activity (C) was evaluated in the open field 
test by counting line crossings and rearings 
during a 10 min observation period. Data repre- 
sent means ± SEM (asterisk, p ~ .05). 
In (B), n = 7 for family 8510 (closed bars) and 
family 8 (gray hatched bars), and n = 8 (stip- 
pled bars) and n = 15 (white hatched bars) for 
control mice of the appropriate strain for the 
neurogenic inflammation test. In (C), n = 7for 
family 8510 (closed bars), n = 10 for family 8 
(gray hatched bars), and n = 8 for control mice 
in the locomotor activity tests (stippled bars and 
white hatched bars). 
Discuss ion 
Much can be learned in the study of the mammalian ner- 
vous system by using methods to interfere in a specific 
manner with the action of selected molecules in vivo. Of 
the methods introduced so far for the mouse nervous sys- 
tem, gene knockout by homologous recombination has 
proved an extremely successful and powerful method for 
generating mice carrying predesigned mutations in the 
germline (Capecchi, 1989). However, because the muta- 
tion, most commonly a null mutation, is introduced in the 
germline of the mutant animals, it will exert its effects from 
the onset of animal development. Although this approach 
to gene inactivation is valuable, for many applications it 
is important hat the inactivation of a particular gene oc- 
curs in a conditional or partial manner (e.g., in a predefined 
Table 1. SP Level in Tissue of Negative and Transgenic Mice 
Tissue Negative (n) Transgenic (n) 
Midbrain 2915 -,- 274 (1 t) 3174 _+ 236 (10) 
Medulla/brainstem 3896 _ 321 (12) 4090 _+ 225 (10) 
Lumbar spinal cord 2245 + 114 (6) 2769 ± 137 (5)" 
Sciatic nerve 371 ::1:13 (12) 544 ± 31 (10) b 
SP levels were determined by radioimmunoassay and are presented 
in femtomoles of protein per milligram of tissue (_-_,- SEM). 
"p < .05. 
b p < .01. 
cell lineage or tissue, or at a certain stage of development), 
and in particular in the adult organism. This would allow 
one to overcome problems posed by the fact that null muta- 
tions in the germline are often lethal, and would also allow 
a more precise and unambiguous analysis of the impact 
of a mutation. While conditional gene targeting now seems 
feasible, through the use of the Cre-loxP recombination 
system (Gu et al., 1993), we have taken a different ap- 
proach (the neuroantibody approach; Piccioli et al., 1991), 
building on work with the expression of recombinant anti- 
bodies in mammalian nonlymphoid cells, as secreted (Cat- 
taneo and Neuberger, 1987) or intracellular (Biocca et al., 
1990; Biocca and Cattaneo, 1995) proteins. Our approach 
is based on the expression of recombinant versions of 
monoclonal antibodies by cells of the nervous system in 
transgenic mice, under the transcriptional control of suit- 
able promoters. The local expression of secreted antibod- 
ies could be used to inactivate a selected gene product 
active in the extracellular environment of the nervous sys- 
tem of transgenic mice. 
Here we report the application of this experimental strat- 
egy to the study of the tachykinin neuropeptide SP. The 
tachykinin gene encodes for multiple peptides and is regu- 
lated by tissue-specific alternative splicing. A gene knock- 
out approach to disrupt the SP-coding region of this gene 
would have to be designed to preserve the expression of 
the other peptides and the correct splicing of the rest of 
the RNA molecule; this would be technically demanding. 
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For this reason, we consider this a case for which the 
neuroantibody approach may be convenient, exploiting 
the NC1/34HL monoclonal antibody, which recognizes 
only the SP peptide and not the related peptides. We have 
generated transgenic mice that express recombinant anti- 
bodies directed against the neuropeptide SP, under the 
transcriptional control of the promoter of the neuronal vgf 
gene, and have shown that the transgenic antibodies, ex- 
pressed in a tissue-specific and developmentally regu- 
lated manner, are indeed able to compete with some bio- 
logical actions of the endogenous SP. 
Neurokinins are a group of structurally related peptides 
characterized by a common C-terminal pentapeptide that 
interact with different receptor subtypes. The neuropep- 
tide SP has multiple actions in the nervous system, some 
of which have been unequivocally demonstrated, while 
others are more controversial or totally unknown. For in- 
stance, SP has been strongly implicated in the transmis- 
sion of pain, being (co)released, alongside other transmit- 
ters and peptides, from small-diameter primary afferents 
and acting primarily on NK1 receptors in the spinal cord. 
However, the involvement of SP as the primary neuro- 
transmitter in acute nociception has been questioned on 
the basis of studies with pharmacological ntagonists. On 
the other hand, the primary role of SP in neurogenic inflam- 
mation, smooth muscle contraction, and vasodilation is 
rather well established. As for the CNS, where the SP 
peptide and its receptor are widely distributed, afunctional 
role(s) is far from clear. The study of the physiological 
effects of neurokinins with respect to neurokinin receptor 
subtypes is hampered by the fact that the endogenous 
neurokinins are themselves preferential, but not selective, 
agonists. This is why competing directly with the ligand 
(as we do in our approach) rather than with receptor antag- 
onists may be preferable. Much work has been performed 
with pharmacological ntagonists, but studies in this field 
have been limited by the lack of efficacious antagonists 
specific for the NK1 receptors, and even more by the diffi- 
culty of using these antagonists in vivo, owing to adminis- 
tration route, short half-life, and side effects. It should also 
be noted that pharmacological antagonists are ideal for 
use in acute preparations, while they are not suited for 
chronic inhibition studies. Our transgenic model goes 
some way in the direction of achieving a more prolonged 
inhibition of the SP neuropeptide, during and after the 
development of the nervous system. This will allow us to 
study not only the effects of the acute block of the peptide, 
but also the modulatory consequences of a more pro- 
longed inhibition of the peptide action on other related 
systems. For example, it will be interesting to utilize this 
mouse model to ask questions related to the development 
of SPergic synaptic pathways under conditions in which 
the action of the peptide is (constantly, albeit partially) 
inhibited. In addition, the recently proposed role of SP as 
a modulator of chemoattractants for commissural axons 
in the spinal cord floor plate (De Felipe et al., 1995) will 
be ideally studied in this mouse model. 
The phenotypic effects caused in adult mice by the ex- 
pression of transgenic antibodies were assessed by be- 
havioral assays related to the SP peptidergic system and 
confirmed that the neutralization of SP action is effective 
in this mouse model, as deduced from the results obtained 
on neurogenic inflammation, which is known to be medi- 
ated by SP and NK1 receptors (Lembeck and Holzer, 1979; 
Lembeck et al., 1992). The inhibition of neurogenic inflam- 
mation by transgenic anti-SP antibodies was observed in 
2 independent lines of transgenic mice, allowing us to rule 
out chromosomal integration effects, The lack of inhibition 
in the acute nociceptive behavioral test is consistent with 
the lack of effect of recently introduced nonpeptide NK1 
antagonists in this phenomenon (Courteix et al., 1993; 
Fleetwoodwalker et al., 1993; Garoes et al., 1993; Yama- 
moto and Yaksh, 1992; Yam amoto et al., 1993). As the role 
of neurokinin peptides is most likely linked to the complex 
dynamic alterations in nociceptive pathways occurring in 
chronic pain (Dray et al., 1994), it is anticipated that the 
transgenic mouse model will reveal alterations in phenom- 
ena such as hyperexcitability, wind-up, and allodynia. This 
will require electrophysiological studies that are presently 
under way. As for the effects on motor activity, it has been 
previously shown that central injections of SP induce loco- 
motion activity, probably owing to activation of the meso- 
limbic pathway via increased release and metabolism of 
dopamine (Kelley and Iversen, 1979; Kelley et al., 1979; 
Naranjo et al., 1984). Consistently, transgenic mice ex- 
pressing anti-SP antibodies how a decreased locomotion 
activity and exploration behavior. Further investigations 
are needed to clarify whether this can be explained by 
changes in the SP-mediated dopamine release in the nu- 
cleus accumbens, and to determine the precise site of 
action of the antibodies in causing these motor deficits. It 
should be noted that, for practical reasons, the behavioral 
assays described in this paper were performed at an age 
(3 months) in which the levels of antibodies are rather low 
and show a high degree of interindividual variability. Thus, 
these effects may have been underscored. 
The immunological consequences of the ectopically ex- 
pressed transgenic antibodies are of great interest and 
are being investigated. Our data show that the serum of 
both families (family 8510 and 8) does not contain mouse 
antibodies directed against the human transgenic ones. 
This shows that transgenic antibodies, being present in 
serum from the early postnatal period, are tolerated by 
the immune system, as demonstrated in other transgenic 
models (Miller et al., 1989; Goodnow et al., 1990). 
It is in principle possible that the secretion of antibodies 
in the nervous system of transgenic mice results in some 
nonspeciflc effect. However, this is unlikely, as previous 
work has shown that neuronal and glial cells secrete re- 
combinant antibodies very efficiently, with no sign of suf- 
fering (Cattaneo and Neuberger, 1987). In the present 
transgenic model, the interaction between the antibody 
and the neuropeptide is most likely to occur in the extra- 
cellular space, as there is no chance for intracellular inter- 
action: antibodies are secreted through the constitutive 
secretory pathway, while the neuropeptide is stored in 
granules of the regulated exocytic pathway. A direct dem- 
onstration of the interference of the antibodies with the 
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synaptically released SP peptide will be provided by elec- 
trophysiological studies of the synaptic transmission in 
these mice. 
The successful application of the neuroantibody ap- 
proach (Cattaneo and Neuberger, 1987; Piccioli et al., 
1991) to interfere in vivo with the action of a target neuronal 
antigen confirms this approach as a complement o that 
of gene knockout by homologous recombination. It is likely 
that an important application of this experimental strategy 
will be in the study of the adult nervous system, with the 
transgenic antibody being kept transcriptionally silent. 
Thus, the neuroantibody approach allows the creation of 
different experimental models for the same target antigen 
of interest, in which the spatiotemporal expression pat- 
terns of the transgenic antibody can differ according to 
the promoter utilized for the transcriptional control of the 
transgene. In the case of the vgf promoter described 
above, the expression of the antibody is mainly postnatal 
and predominantly restricted to the CNS, while the anti- 
body levels found in the serum are rather low and most 
probably reflect the secretion of antibodies from cells of 
neuroendocrine origin, or from cells of the adrenal me- 
dulla. The overall phenotype observed in the vgf anti-SP 
mice is rather mild, probably as the antibodies are mainly 
acting postnatally. It will be interesting to compare it with 
that obtained in mice in which the same antibody is ex- 
pressed earlier in development (A. C. and P. P., unpub- 
lished data). 
The range of proteins that can be studied by this ap- 
proach is not limited to those acting extracellularly, as 
recombinant antibodies have been successfully targeted 
to different intracellular compartments, where they can 
compete with the corresponding antigen (Biocca and Cat- 
taneo, 1995). As further applications of the neuroantibody 
approach are pursued (Ruberti et al., 1993), it will be possi- 
ble to evaluate further the power and limitations of this 
antibody-based phenotypic knockout for functional studies 
in the developing and adult nervous system. 
Experimental Procedures 
Production of Transgenic Mice 
The plasmids pSVhygro-VGF8aV~SP and pSVgpt-VGF8aVHSP, car- 
rying the light and heavy chain genes of the chimeric antibody NCI/ 
34HL (Piccioli et al., 1991) under the transcriptional control of the 
NGF-inducible rat gene vgf(Levi et al., 1985), were digested at comple- 
tion with Pvul and HindllI-Bglll, respectively, to isolate the transcrip- 
tional unit. While the transcriptional unit for the heavy chain did not 
include vector sequences, that for the light chain did, alongside two 
enhancer sequences from immunoglobulin genes (see Figure 1). The 
8.9 and 5.1 kb fragments containing the transcriptional units for the 
light and heavy chains, respectively, were electrophoresed in 0.7% 
low melting point agarose and then purified by NACS 52-PREPAC 
column (BRL). A total of 1-2 pl of each of the purified DNA samples 
(1-2 ng/ml) was coinjected in the male pronucleus of 1-cell fertilized 
eggs from F1 (C57BL/6J x CBaF1), and 12-24 hr later, injected eggs 
were reintroduced in the oviduct of pseudopregnant foster females 
F1 (C57BL/6J x CBNCa), as described (Allen et al., 1987). Family 8 
mice were obtained in a set of separate experiments using the plas- 
mids based on pSVhygro-lgV,SP and pSVgpt-lgV,SP (Piccioli et al., 
1991). Microinjections were performed in C57BU6 x SJLF2 hybrid 
mouse eggs (DNX Corp.) 
Analysis of vgf anti-SP mice was performed by Southern blot and 
dot blot. Briefly, 20 I~g of genomic DNA from tail biopsies was digested 
with BamHI using 32P-labeled DNA fragments encompassing human 
constant regions as probes. For the heavy chain, a BamHI-Bglil frag- 
ment was purified from the vector pSVgpt-VGF8aV, SP, while for the 
light chain we used a Sacl fragment from plasmid pSVhygro- 
VGF8aV,SP. Probes labeled with 32p to a high specific activity by 
random priming were used under high stringency hybridization (50% 
formamide, 6x SSC, 5 x Denhardt's, 0.5% SDS, 0.2 mg/ml sonicated 
salmon sperm DNA at 42°C) and washing (0.2x SSC, 0.1% SDS at 
65°C) conditions. 
RNA Analysis 
Anesthetized mice were sacrificed, and tissues were dissected, imme- 
diately frozen in liquid nitrogen, and stored at -70°C until use. Total 
RNA was isolated following the guanidine-isothiocyanate procedure 
(Chomcynzski and Sacchi, t 987) and analyzed by RNase protection 
assay, using the following probes: V. (PstI-BamHI; 555 bp) from M13- 
IgP-VHSP (Piccioli et al., 1991) cloned in Bluescript KS(+) and cut 
with PstI-BamHI; and V, (PvulI-BamHI; 466 bp) from M13-1gP-V~SP 
(Piccioli et al., 1991) cloned in Bluescript KS(+) and cut with Smal- 
BamHI. 
Pvull fragments from these vectors (983 and 903 bp, respectively) 
were used as templates for RNA transcription with T7 polymerase in 
the presence of [3~P]UTP (Amersham; 800 Ci/mmol). The size of the 
expected protected band is 345 bp for VH and 309 bp for V~. 
The probe for vgfmRNA was a BamHI-Sphl, 580 bp fragment (corre- 
sponding to amino acids 443-635 of the VGF protein, in the 3' region of 
the rat vgf gene, which is most conserved across species) in pGEM4Z 
(kindly provided by R. Possenti). The RNA probe was transcribed with 
T7 polymerase. 
V,, V,, and vgf antisense RNA probes were hybridized (or cohybrid- 
ized) to 20 pg of RNA in 80°/0 formamide (46°C for 12-18 hr) and 
treated with RNase A and TI. Protected RNA fragments were electro- 
phoresed through a 4%-6% acrylammide, 8 M urea gel and autoradio- 
graphed. 
SP and AnU-SP Antibody Measurements in the Serum 
and in Tissues 
SP levels were determined essentially as in Donnerer et al. (1992)• 
Briefly, the tissue samples from brain were placed in 20 vol of 2 N 
acetic acid, heated three times for 10 s each in a microwave oven to 
destroy peptidase activity, and homogenized by sonication. Homoge- 
nates were centrifuged, and the supernatants were freeze dried. SP 
immunoreactivity onthe reconstituted samples was determined using 
rabbit polyclonal antibody RD2 (S. Leeman) and 12Sl-labeled Bolton- 
Hunter-SP (Amersham) as tracer. 
For the determination of human anti-SP antibodies in the serum by 
ELISA, transgenic and wild-type mice were bled from the retro-orbital 
sinus starting from P16, whereas younger animals were sacrificed and 
blood was collected transcardially under slight anesthesia conditions. 
Serum (50 p.I) from each separate mouse was tested by ELISA on 
plates coated with SP conjugated to bovine serum albumin (SP-BSA; 
5 mg/ml). Specifically, bound human/rat anti-SP antibodies were de- 
tected using a 1:750 dilution of horseradish peroxidase-linked goat 
anti-human immunoglobulin antibodies (Amersham) and developed 
with 1-Step Turbo TMB ELISA (Pierce). The presence of mouse anti- 
human antibodies was detected using biotinylated goaPanti-mouse 
antibodies at a 1:2000 dilution (Vector) followed by a 1:500 dilution of 
streptavidin-horseradish peroxidase (Amersham). For the determina- 
tion of ~2sI-SP-binding antibodies in the blood, 100 p,I of serum was 
preincubated for 5 hr at 4°C in radioimmunoassay buffer (8 mM 
NaH2PO4, 43 mM Na2HPO,, 3 mM NAN3, 145 mM NaCI, 0•1% albumin, 
0.1o/0 gelatin, 0.1% Triton X-100); 15-20 fmol of 12sI-SP was then 
added, and the reaction was left to react for 36 hr at 4°C. Labeled 
SP was separated by the addition of 2 vol of charcoal/dextran T70 
separation buffer (9.5 mM NaH2PO4, 40 mM Na2HPO4, 3 mM NAN3, 
145 mM NaCI, 0.625% charcoal/0.0625o/0 dextran T70). The bound 
fraction (supernatant) was separated 30 min later by centrifugation at 
2000 x g for 15 rain, and the radioactivity was counted. Tissue extracts 
were prepared from brain regions of 20-day- and 3-month-old mice 
(single-transgenic, double-transgenic, and controls). Tissue (0.1-0.5 
g) was extracted in 1-2 ml of ice-cold homogenization buffer (125 
NaCI, 50 mM Tris, 1 mM EDTA, 1 mM EGTA, 0.5O/o Nonidet P=40 [pH 
7.4], and protease inhibitors [1 mM phenylmethylsulfonyl fluoride, 100 
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p.g/ml aprotinin, 100 p,g/ml leupeptin, 20 p.g/ml chymostatin]) with a 
Polytron homogenizer. The homogenate was then subjected to a low 
speed centrifugation, and the soluble fraction was separated by a high 
speed centrifugation (100,000 x g for 30 min). The protein content 
of the $100 fraction was determined by the Lowry method, before 
antibody purification on a protein A-Sepharose column. Eluted anti- 
bodies were then challenged with 15-20 fmol per experimental point 
of 12Sl-labeled Bolton Hunter-SP (Amersham), and the amount of anti- 
bedy-beund SP was determined in duplicates, as described above. 
Standard calibration curves were run in each experiment, with serial 
dilutions of the affinity-purified NCl/34HL antibody. The background 
values obtained for nontransgenic controls and for the light chain 
transgenic mice were always between 0.4% and 4%. 
Immunocytochemistry 
Mice were anesthetized with Nembutal (0.1 ml per 100 g of body 
weight) and transcardially perfused with 4% paraform aldehyde in PBS. 
Brains and spinal cord were removed and postfixed overnight, cryopro- 
tected in 20% sucrose in PBS, frozen in dry ice, and stored at -70°C 
until cutting. Cryostat sections (40-50 p.m) were incubated in 0.003% 
H202, 10% fetal calf serum (FCS) in PBS before being analyzed as 
floating sections for the presence of transgenic antibody chains using 
the avidin-biotin-peroxidase Elite Standard kit (Vector Laboratories). 
Biotinylated anti-human IgG (Ame rsham) at 1:500 (0.1%0 Triton X-100, 
10%o FCS in PBS) and anti-human light chain chain (Amersham and/ 
or Vector) at 1:50-1:100 were used as primary antibodies. Sections 
from age-matched control mice were also analyzed in parallel under 
the same conditions, in addition to sections in which primary antibodies 
were omitted. 
Functional end Behavioral Experiments 
The vgf anti-SP transgenic mice were used for the experiments at the 
age of 2-3 months. Basically, the same animals were used for all three 
functional tests, in the following order: open field tests, nociceptive 
tests, and neurogenic inflammation tests, with a 1 week interval be- 
tween the individual tests. Family 8 mice have been systematically 
tested for Iocomotory activity and neurogenic inflammation tests, and 
in a preliminar way for acute nociception. 
For the hot plate test, mice were placed on a 55°C hot aluminium 
plate 19 cm in diameter with a 20 cm high perspex cylinder. Licking 
of the hindpaws or jumping was used as endpoint. For the tail with- 
drawal test, mice were held in tubular restraining cages, and the termi- 
nal two-thirds of the tail were dipped into water at 50°C. In the open 
field test, mice were placed in a square box of 80 x 80 x 40 cm. A 
grid of black lines 10 cm apart was painted on the floor. The box was 
illuminated with a 60 W bulb positioned 80 cm above the floor. The 
mice were videotaped, and the following activities were counted for 
10 min: locomotor activity (number of lines crossed) and rearing. The 
box was cleaned with alcohol after each animal. The data were col- 
lected from animals entering the apparatus for the first time. In the 
test for mustard oil-induced neurogenic inflammation, mice were an- 
esthesized with sodium pentobarbitone (50 mg/kg, intraperitoneally), 
and the jugular vein was exposed to inject Evans blue (30 mg/kg). 
After a 5 min waiting period, mustard oil (5% in paraffin oil, 15 min 
contact time) was applied on the dorsal skin of one hindpaw, and the 
contralateral paw was used as a control (paraffin oil application alone). 
The level of extravasated protein-bound Evans blue in the paw was 
determined (620 rim) after formamide xtraction. Data were analyzed 
using the Mann-Whitney test. 
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